Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asp-PSC aspirin trial in primary sclerosing cholangitis
ISRCTN12358813Phase 3Recruiting
- Sponsor
- Imperial College London
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) and inflammatory bowel disease (IBD) comparing Aspirin with Placebo (2 arms). Primary endpoint: Composite primary endpoint. Started Jan 2024; status: recruiting.
02
Drugs
aspirin
03
Conditions
Primary Sclerosing Cholangitis (PSC)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ISRCTN12358813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12358813.